All In Biotech

Drug Trial Radar · NCT02297945

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks

Last checked: Nov 20, 2026Latest source record: Sep 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

50

Actual

Start

Apr 2015

Primary completion

Nov 2019

Study completion Apr 29, 2020

Sponsor

Lead sponsor
HRA PharmaIndustry
Sponsor type
Industry
First posted
Nov 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.

Conditions

  • Cushing's Syndrome

Interventions

  • metyraponeDrug

    Single arm study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Normalization of cortisol levels (urinary free cortisol)Time frame: 3 months

Locations

36 sites in 8 countries. Site status is shown where the registry gives one.

  • University hospital Antwerp

    Antwerp, Belgium

  • CHU Erasme

    Brussels, Belgium

  • University hospital Saint Luc

    Brussels, Belgium

  • CHU Liège

    Liège, Belgium

  • Charité Berlin

    Berlin, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Munich university

    Munich, Germany

  • University hospital Wuerzburg

    Würzburg, Germany

  • State health center

    Budapest, Hungary

  • Semmelweis Egyetem II. Belgyógyászati Klinika

    Budapest, Hungary

  • University Debrecen

    Debrecen, Hungary

  • University of Pecs

    Pécs, Hungary

  • University of Szeged

    Szeged, Hungary

  • Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Ospedale San Luca IRCCS Istituto Auxologico Italiano

    Milan, Italy

  • S. Giuseppe Hospital

    Milan, Italy

  • Federico II University

    Naples, Italy

  • University of Padova

    Padova, Italy

  • University of Turin

    Turin, Italy

  • San Luigi Gonzaga Hospital, University of Turin

    Orbassano, Turin, Italy

  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

    Gliwice, Poland

  • University Hospital

    Krakow, Poland

  • University Clinical Hospital

    Wroclaw, Poland

  • Institutul National de Endocrinologie 'C.I Parhon' - Endocrinologie II

    Bucharest, Romania

  • Institutul National de Endocrinologie 'C.I Parhon' - Endocrinologie VI

    Bucharest, Romania

  • Spitalul Universitar de Urgenta Militar Central 'Dr Carol Davila'

    Bucharest, Romania

  • Spitalul Clinic Judetean de Urgenta Cluj-Napoca

    Cluj-Napoca, Romania

  • S.C Centrul Clinic Mediquest SRL

    Sângeorgiu de Mureş, Romania

  • Spitalul Clinic Judetean de Urgenta Sibiu

    Sibiu, Romania

  • Spitalul Clinic Judetean Mures

    Târgu Mureş, Romania

  • University hospital clinic of Barcelona

    Barcelona, Spain

  • Hospital Universitario La Ribera

    Valencia, Spain

  • Ankara Numune Training and Research Hospital

    Ankara, Turkey (Türkiye)

  • Dokuz Eylul UMF

    Izmir, Turkey (Türkiye)

  • Ondokuz Mayıs University Medical Faculty

    Samsun, Turkey (Türkiye)

  • Karadeniz Teknik University

    Trabzon, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.